Antiviral prophylaxis versus preemptive therapy to prevent cytomegalovirus infection and related death in liver transplantation: a retrospective study with propensity score matching.

[1]  A. Webster,et al.  Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. , 2013, The Cochrane database of systematic reviews.

[2]  V. Emery,et al.  Cytomegalovirus in transplantation – challenging the status quo , 2007, Clinical transplantation.

[3]  D. Snydman,et al.  Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  J. Preiksaitis,et al.  Canadian Society of Transplantation Consensus Workshop on Cytomegalovirus Management in Solid Organ Transplantation Final Report , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[5]  Nina Singh,et al.  Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  M. Pescovitz,et al.  Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients , 1997, The Lancet.

[7]  P. Sweny.  Infection in solid organ transplant recipients , 1989 .

[8]  D. Rubin,et al.  The central role of the propensity score in observational studies for causal effects , 1983 .

[9]  Angela M Caliendo,et al.  International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. , 2010, Transplantation.